Ovid Therapeutics Inc (OVID NASDAQ) stock market data APIs
$1.1971
0.1(8.4%)
as of November 13, 2025
Try our APIs with
free plan!
Ovid Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Prev. Close
1.1971
Open
1.2959
High
1.3252
Low
1.1682
52 wk Range
0.2425-2.01
Market Cap
85 455 K
Shares Outstanding
71 212 K
Revenue
6 651 K
EPS
-0.17
Beta
0.076
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Ovid Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Ovid Therapeutics Inc data using free add-ons & libraries
Get Ovid Therapeutics Inc Fundamental Data
Ovid Therapeutics Inc Fundamental data includes:
- Net Revenue: 6 651 K
- EBITDA: -41 205 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -0.15
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ovid Therapeutics Inc News
New
Ovid Therapeutics GAAP EPS of -$0.17 misses by $0.02, revenue of $0.13M misses by $0.04M
* Ovid Therapeutics press release [https://seekingalpha.com/pr/20303367-ovid-therapeutics-announces-planned-leadership-succession-and-reports-business-updates-and] (OVID [https://seekingalpha.com/sy...
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of DirectorsNext-generation GABA-aminotransferase (GABA-AT)...
QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer
QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer Physician-scientist brings more than two decades of R&D leadership experience in neuroscience, rare disease, and pain m...
MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates
MannKind (MNKD) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.04 per share a year ago. These figures are...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
